FDA Opens Comment Docket on VOQUEZNA Exclusivity Challenge
Phathom Pharmaceuticals said the FDA opened a public docket on legal and regulatory questions related to a challenge to VOQUEZNA’s NCE exclusivity through May 3, 2032.
Phathom Pharmaceuticals said the FDA opened a public docket on legal and regulatory questions related to a challenge to VOQUEZNA’s NCE exclusivity through May 3, 2032.